Clinical Trials List
Protocol Number202409007MIPE
NCT Number(ClinicalTrials.gov Identfier)-
Active
2024-10-01 - 2030-12-31
Phase II
Recruiting1
ICD-10C15.3
Malignant neoplasm of upper third of esophagus
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9150.0
Malignant neoplasm of cervical esophagus
-
-
Trial Applicant
-
Sponsor
-
-
Trial scale
Taiwan Single Center
-
Update
2026/05/13
Investigators and Locations
Principal Investigator
Chih-Hung Hsu
Co-Principal Investigator
- 吳宗哲 Division of Hematology & Oncology
- FENG-MING HSU Division of Hematology & Oncology
- TA-CHEN HUANG Division of Hematology & Oncology
- 江旴恆 Division of General Surgery
- JANG-MING LEE Division of General Surgery
- JHE-CYUAN GUO Division of Hematology & Oncology
- JEI-YIE HUANG Division of Nuclear Medicine
- 江韻 Division of Hematology & Oncology
- 莊建淮 Division of Hematology & Oncology
- 陳克誠 Division of General Surgery
- MEI-FANG CHENG Division of Nuclear Medicine
- Chia-Hsien Chen Division of Hematology & Oncology
- 呂紹綸 Division of Hematology & Oncology
- 郭弘揚 Division of Hematology & Oncology
- 黃培銘 Division of General Surgery
The Actual Total Number of Participants Enrolled
0 Recruiting
Study Contacts
- -
Condition/Disease
-
Objectives
-
Test Drug
-
Active Ingredient
-
Dosage Form
-
Dosage
-
Endpoints
-
Inclution Criteria
-
Exclusion Criteria
-
The Estimated Number of Participants
-
Taiwan
50 participants
-
Global
50 participants